Lancaster, CANCT03550391Now EnrollingIRB Ready

Brain Metastases Clinical Trial in Lancaster, CA

Access cutting-edge brain metastases treatment through this phase 3 clinical trial at a research site in Lancaster. Study-provided care at no cost to qualified participants.

Sponsored by Canadian Cancer Trials Group

Quick Self-Assessment

See if you qualify for this Lancaster location

Preparing your pre-screening questions…

Expert Care in Lancaster

Access brain metastases specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related brain metastases treatment provided free

Apply for This Lancaster Location

Check if you qualify for this brain metastases clinical trial in Lancaster, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Lancaster

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Lancaster site if eligible
  4. 4Begin participation

About This Brain Metastases Study in Lancaster

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hipp

Sponsor: Canadian Cancer Trials Group

Who Can Participate

Inclusion Criteria

Patients must have 5 or more brain metastases as counted on a T1 contrast enhanced MRI obtained ≤ 30 days from randomization (maximum 15 brain metastases).
Patients must have a pathological diagnosis (cytological or histological) of a non-hematopoietic malignancy.
The largest brain metastasis must measure \<2.5 cm in maximal diameter.
Centre must have the ability to treat patients with either a Gamma Knife, Cyberknife, or a linear accelerator-based radiosurgery system.
Patient must be \> 18 years of age.
Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French either alone or with assistance.
ECOG performance status 0, 1, or 2.
Creatinine clearance must be ≥ 30 ml/min within 28 days prior to registration.
The Neurocognitive Testing examiner must have credentialing confirming completion of the neurocognitive testing training.
Facility is credentialed by IROC to perform SRS and HA-WBRT. The treating centre must have completed stereotactic radiosurgery credentialing of the specific system(s) to be used in study patients. The treating centre must have completed IMRT credintialing of this specific IMRT systems to be used in study patients for the purposes of HA-WBRT.
Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrolment in the trial to document their willingness to participate.
A similar process must be followed for sites outside of Canada as per their respective cooperative group's procedures.
Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
In accordance with CCTG policy, protocol treatment is to begin within 14 days of patient enrolment.
Women/men of childbearing potential must have agreed to use a highly effective contraceptive method.

Exclusion Criteria

Pregnant or nursing women.
Men or women of childbearing potential who are unwilling to employ adequate contraception.
Inability to complete a brain MRI.
Known allergy to gadolinium.
Prior cranial radiation therapy.
Planned cytotoxic chemotherapy within 48 hours prior or after the SRS or HA-WBRT.
Primary germ cell tumour, small cell carcinoma, or lymphoma.
Widespread definitive leptomeningeal metastasis. This includes cranial nerve palsy, leptomeningeal carcinomatosis, ependymal involvement, cranial nerve involvement on imaging, suspicious linear meningeal enhancement, or cerebrospinal fluid (CSF) positive for tumour cells.
A brain metastasis that is located ≤ 5 mm of the optic chiasm or either optic nerve.
Surgical resection of a brain metastasis (stereotactic biopsies will be allowed).
More than 15 brain metastases on a volumetric T1 contrast MRI (voxels of 1mm or smaller) performed within the past 14 days, or more than 10 metastases in the case of a non-volumetric MRI.
Prior allergic reaction to memantine.
Current alcohol or drug abuse.
Current use of NMDA antagonists, such as amantadine, ketamine, or dextromethorphan.
Diagnosis of chronic liver disease/cirrhosis of the liver (e.g. Child-Pugh class B or C).
Patients with architectural distortion of lateral ventricular systems, which, in the opinion of the local investigator, makes hippocampal delineation challenging

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lancaster?

Yes, this clinical trial (NCT03550391) has an active research site in Lancaster, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Brain Metastases Treatment Options in Lancaster, CA

If you're searching for brain metastases treatment options in Lancaster, CA, this clinical trial (NCT03550391) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lancaster research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced brain metastases specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all brain metastases clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Lancaster, CA

See all brain cancer clinical trials recruiting in Lancaster — not just this study.

Browse Brain Cancer Trials in Lancaster →

Browse More Trials by Condition

Brain Cancer TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Lancaster?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Lancaster, CA